NCT05155566View on ClinicalTrials.gov

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

CompletedOBSERVATIONAL
Enrollment

847

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Breast Cancer Metastatic
Trial Locations (2)

Unknown

Pfizer country office, Buenos Aires

SK105JB

Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK, Bollington

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05155566 - Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. | Biotech Hunter | Biotech Hunter